Is Compounded Semaglutide Safe? What the Evidence Shows
No trial exists, so the safety record was assembled afterward from poison control calls, FDA reports, and a great many confused syringes.

One thing that happens when a drug reaches millions of people without a clinical trial is that its safety record gets assembled afterward, out of whatever people happen to report. Compounded semaglutide is the clearest current example. If you typed “is compounded semaglutide safe” into a search box, the honest answer is that nobody has run the study that would settle it. The site Compounded Semaglutide Dosage Chart notes that the product “is not FDA-approved as a finished drug product and has not been reviewed by the FDA for safety, effectiveness, or quality,” and a regulatory explainer, Compounded Semaglutide: Meaning and Why Regulators Warn, says it “has zero randomized trial data supporting its safety or efficacy.”
What does exist is a pile of after-the-fact evidence: FDA adverse event reports (520 of them related to compounded semaglutide by April 30, 2025), poison control case reports, and FDA inspection findings about what was in the vials. Most of that evidence describes one specific failure. People drew up the wrong amount from a multi-dose vial, sometimes five to 20 times the intended dose. Problems with the drug itself (weak potency, unapproved salt forms) are documented too, but whether they hurt anyone, and how often, is not settled.
Is compounded semaglutide safe, and what would count as an answer
For purposes of this article, and with the gravity the subject deserves, “safe” shall mean that a drug has been tested in controlled conditions, compared against something, and found to do what it says without doing too much else. Under that definition the question cannot be answered in the affirmative, because the test was never held. Compounded semaglutide “is not tested for safety, potency, or effectiveness before use,” per the same explainer. A pharmacist writing at PrecisionOptimize adds that it “has never undergone FDA bioequivalence testing,” which generics have to do.
That leaves a weaker definition: safe enough, judged by how often reports of harm show up. That is the definition the actual evidence speaks to. It is a different question.
Who gets paid at each step from shortage to syringe
Start with Novo Nordisk, which sells semaglutide in prefilled pens. A pen basically decides the dose for you. Then demand outran supply, semaglutide went on the FDA shortage list, and the law let compounders make their own versions while the shortage lasted. Compounders were filling a real gap, which is what the shortage rules are for.
What they sold was usually a vial and some syringes. Telehealth brands built businesses on selling those vials, typically for between $150 and $400 a month. To be fair to everyone, a patient choosing that over the branded price was making an entirely sensible choice, and a company offering it was doing the obvious thing a company does.
The trouble is the format. A case series reported to a poison control center put it this way: “Vials of compounded semaglutide do not include the safety features provided by prefilled manufactured pens, making large overdoses (e.g., 10-fold dosing errors) possible.” A pen is like a coffee machine that takes pods. A vial is a bag of beans and an unmarked scoop. Both make coffee.
One link down, the patient has to do arithmetic. The prescription is in milligrams, the vial is labeled by concentration in milligrams per milliliter, and the syringe is marked in units. The FDA said confusion among those three “may have contributed” to dosing errors. This is the Stonehenge scene in Spinal Tap, where a drawing in inches gets built in feet, except the miniature version is the one you wanted. In the 2023 case series, one patient got a vial and syringes with no pharmacist counseling at all, and another dosed in milliliters and units rather than milligrams. (I write about syringe units for a living and would still want someone to check my work.)
The next link is poison control. Calls about injected weight loss drugs rose more than 15-fold since 2019, with many relating to dosing errors more common with compounded multi-dose vials. Then the FDA, which collects reports. Then Novo Nordisk, which by August 5, 2025 had filed 132 complaints in federal courts across 40 states, citing patient safety. (Its press release puts “semaglutide” in scare quotes when referring to the compounded kind, a typographical decision I will simply admire and not interpret.) On the other hand, Novo selling the pens and suing the vials is also just a company doing the obvious thing a company does.
What the poison control and FDA reports actually show
On July 29, 2024, the FDA issued a MedWatch alert about dosing errors with compounded injectable semaglutide. The agency said the majority of its reports described patients “mistakenly drawing up more than the prescribed dose from a multiple-dose vial during self-administration.” Patients took five to 20 times the intended amount. Some were hospitalized. Reported effects included nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones.
The FDA also warned that multiple concentrations may be on the market and told providers to call the compounder if they were unsure. That is a sensible instruction. It also tells you something about the market.
Here is an invented scenario, clearly not something that happened. A compounder makes its vial twice as concentrated, so it ships less liquid. A competitor doubles again. Eventually one syringe tick is a month of drug, and the pharmacist at the counter says, “So you just want to sort of think about it and inject a little bit.” Nobody in this chain made a bad decision. The chain did.
The 2023 case series is small: three patients, from compounding pharmacies and an aesthetic spa, two of whom gave themselves 10-fold errors. The point is that small case series are what you get when there is no trial.
What testing and inspections found inside the vials
The drug itself is a separate question, and the evidence is thinner. FDA warning letters have cited compounded semaglutide measured at 79.9% of labeled potency. Early safety signals included unapproved salt forms, semaglutide sodium and semaglutide acetate, and non-sterile compounding environments. No clinical studies show that those salt forms behave like the semaglutide base used in research. The FDA also found that Empower Clinic Services made semaglutide and tirzepatide products that looked like copies of approved drugs.
On sourcing, a Brookings Institution report cited by Novo said many products rely on active ingredients imported from facilities in China lacking FDA oversight. Novo also alleged Hims & Hers used “inauthentic API,” and sued Hims & Hers on February 9, 2026, for patent infringement. Those are allegations in a lawsuit, not findings. The site’s article on independent lab testing covers the testing results in detail.
The PrecisionOptimize pharmacist’s read is that most MedWatch events for compounded semaglutide “appear to be dosing errors rather than formulation failures.” I assume that is roughly right as a description of the reports. It is not the same as saying formulations are fine.
What the FAERS studies can and cannot tell you
FAERS is the FDA’s adverse event reporting database, and it is voluntary (which is a polite way of saying it counts whoever bothered). A pharmacovigilance study (PMID 40285721) looked at compounded liraglutide, semaglutide and tirzepatide reports from 2018 to 2024; its specific findings are not in the material here, so I won’t characterize them. A larger study covering 2021 through early 2026 found 243,114 GLP-1 primary-suspect records, 55,619 of them semaglutide, with “incorrect dose administered” among the frequent terms. That count covers GLP-1s generally, not just compounded ones.
I mean, think about what FAERS can capture. A dramatic overdose sends someone to a hospital, and someone files a report. A vial at 79.9% potency mostly produces a patient who loses less weight and assumes it is them. Weak drug is quiet. Ten times the drug is loud.
So the database is, for instance, much better at counting syringe mistakes than at detecting a slightly wrong product. Whether the formulation problems cause harm at a meaningful rate is not something these reports can settle.
Why the evidence ends up being about arithmetic
The semaglutide shortage ended in February 2025, and the FDA’s deadline for 503B facilities to stop new batches was May 22, 2025. The FDA declined to put semaglutide on the 503B bulks list. Some sellers kept going anyway: a secret shopper study found 92% of 75 businesses selling compounded semaglutide, and the FDA sent telehealth warning letters in September 2025, February 2026 and June 2026. Hims & Hers advertised a compounded semaglutide tablet on February 5, 2026. Tablets, at least, do not come with syringe units.
Each party here did something reasonable. The result is that the best-documented safety question about compounded semaglutide is not about the semaglutide at all.
It is about how the vial meets the syringe, which means the most thorough safety record this drug has is a national survey of how people read the side of a syringe.
Sources
- Administration errors of compounded semaglutide reported to a poison control center-Case series
- Compounded Semaglutide: Meaning and Why Regulators Warn
- Compounded Semaglutide Dosage Chart: Titration Guide
- Novo Nordisk expands legal action to protect US patients from unsafe, non-FDA-approved compounded "semaglutide"
- Compounded Semaglutide vs. Ozempic: What's the Difference? | PrecisionOptimize
- Semaglutide Compounding Pharmacy: What's Legal In 2026
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system
- FDA MedWatch - FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products
- Quality Control In Compounding Pharmacy: 2026 Checklist
- FDA alerts health care providers, compounders of dosing ...
- FDA and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown. What’s Next? | Pharmacy Times
- FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’ - BioSpace
- America's Poison Centers - GLP-1
- The Shot Heard ‘Round the Pharmacy’: FDA Takes Aim at GLP-1 Compounders | ArentFox Schiff
- Businesses continue to sell compounded semaglutide, tirzepatide
- Compounded Semaglutide vs Brand Name Comparison: What's Actually in Your Injection?
- Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping Study.
- Compounded GLP-1s: Why doctors worry and the FDA is cracking down
- FDA Warning Letters to Telehealth Companies Selling Compounded Drugs
- The Semaglutide Shortage Is Ending: What’s Next For Compounded Drugs?
- Compounded GLP-1 Marketing After the Shortage Ended
Compound GLP explains the law and published research. It is not medical or legal advice, and it never recommends a dose, a pharmacy or a product. Talk to a clinician before you start, stop or change any medicine.